ArticleJournal of cardiovascular electrophysiology2026
Prevalence and Recovery of Arrhythmia-Induced Cardiomyopathy in Patients With Newly Diagnosed Heart Failure Using a Wearable Defibrillator: A Real-World Cohort Study.
Article in Journal of cardiovascular electrophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Wearable Cardioverter-Defibrillator in Patients at Transient Risk of Sudden Cardiac Death: State of the Art and Contemporary Clinical Evidence.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArrhythmia-induced cardiomyopathy (AIC) is a potentially reversible cause of heart failure triggered by different sustained arrhythmias, but data on its real-world prevalence, recognition, and outcomes are limited.
objectiveTo assess frequency, predictors, and outcomes of AIC in patients with newly diagnosed left ventricular systolic dysfunction (LVSD) and concurrent arrhythmia undergoing early rhythm control with a wearable cardioverter-defibrillator (WCD).
methodsAmong 780 WCD-treated patients (2017-2023), those with newly diagnosed idiopathic LVSD (LVEF < 35%) and persistent arrhythmia (atrial fibrillation/flutter or > 20% ventricular ectopy) were included. Diagnostic workup comprised echocardiography, coronary angiography, and cardiac MRI. Effective rhythm control was achieved via cardioversion, antiarrhythmic drugs, and/or ablation. Follow-up was up to 6 months. AIC was defined as LVEF improvement > 15% with restored sinus rhythm or suppressed ventricular ectopy.
resultsOf 780 WCD patients, 142 (18.2%) had LVSD with arrhythmia; 74 idiopathic cases were analyzed. At a mean follow-up of 138 days (4.5 months), 54 patients (73%) maintained sinus rhythm or suppressed ventricular ectopy after rhythm control, of whom 32 (59.3%) fulfilled AIC criteria. LVEF improved from 28% to 43% in AIC; 56.3% of AIC patients fully recovered (> 50%). Non-AIC patients had larger LV dimensions, lower heart rates, more mitral regurgitation, and a non-significant trend toward more frequent late gadolinium enhancement (p = 0.073). No parameter reliably predicted AIC; LVEF < 25% predicted lack of full recovery (p = 0.040). No appropriate WCD shocks occurred. ICD indication decreased from 100% to 17% post-therapy in AIC and Non-AIC patients (3.1% vs. 36.4%, p = 0.001).
conclusionsAIC related to atrial fibrillation, flutter, or frequent ventricular ectopy is more prevalent and reversible than often recognized. Early rhythm control under WCD protection, supported by comprehensive diagnostics, allows identification of reversible LVSD and may help prevent unnecessary ICD implantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.